Where Will The Terrorists Strike Next? - - BioPharm International


Where Will The Terrorists Strike Next?

BioPharm International
Volume 18, Issue 8

Shortly after London's ordeals, I heard of a new piece of intelligence suggesting that a large pharmaceutical company is on a short list of possible Al Kaeida targets. Since I'm sure all pharmaceutical facilities are securely buttoned up, I wonder more about our industry as a whole becoming a focus of attack by these maniacal extremists.

By now you've no doubt heard how Colombian drug lords nixed a lucrative deal several years back with Osama bin Laden, who'd offered to buy a large quantity of their cocaine to then lace with poison before orchestrating its distribution to American users. Lucky for us the drug lords considered the bottom line and decided that partnering with bin Laden, or anyone else planning to taint their product, was bad for business.

But if bin Laden and his ilk already tried using illegal drugs as a delivery mechanism of death, will they attempt duplicating the scheme with legitimate drugs? In particular, our teenagers' susceptibility is a concern. Columbia University recently reported that about 2.3 million youth between the ages of 12 to 17 took legal medications illegally in 2003. Some teens evidently buy their drugs from questionable internet pharmacies that don't require prescriptions.

Hopefully, the terrorists can't access the capabilities to pull off such a scenario. Maybe they've already realized they'd have little control over which users ordered their product. After all, there's no telling when even a bin Laden loyalist outside the inner circle might one day reach for a bottle of oxycontin procured from a suspicious internet pharmacy. Of one thing I'm sure. It's a good time to steer clear of any medication whose source is of a dubious nature.

Carol L. Fisher, Editor in Chief
BioPharm International

blog comments powered by Disqus



Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here